Telmisartan/amlodipine

{{Short description|Combination drug}}

{{Use dmy dates|date=February 2025}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Drugbox

| type = combo

| component1 = Telmisartan

| class1 = Angiotensin II receptor antagonist

| component2 = Amlodipine

| class2 = Calcium channel blocker

| tradename = Twynsta, others

| MedlinePlus =

| DailyMedID = Telmisartan and amlodipine

| pregnancy_AU =

| pregnancy_category =

| routes_of_administration = By mouth

| ATC_prefix = C09

| ATC_suffix = DB04

| legal_AU = S4

| legal_AU_comment = {{cite web | title=Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017 | access-date=30 March 2024}}

| legal_CA = Rx-only

| legal_CA_comment = {{cite web | title=Twynsta Product information | website=Health Canada | date=11 August 2011 | url=https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85622 | access-date=17 February 2025}}

| legal_UK =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Twynsta (telmisartan/amlodipine) tablets, for oral use Initial U.S. Approval: 2009 | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=599206 | access-date=18 March 2023}}

| legal_status =

| CAS_number = 2087526-77-8

| PubChem =

| KEGG = D09743

}}

Telmisartan/amlodipine, sold under the brand name Twynsta among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of telmisartan, an angiotensin II receptor antagonist; and amlodipine, as the besilate, a calcium channel blocker. It is taken by mouth.{{cite web |title=DailyMed - Telmisartan and Amlodipine tablet |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b438b4-4874-43f4-a50a-4e6f3e5530ac |website=DailyMed |accessdate=30 October 2019}}

Common side effects include dizziness, swelling, and back pain. Severe side effects may include low blood pressure, kidney problems, electrolyte problems, and a heart attack. Use during pregnancy may harm the baby. Telmisartan works by blocking the effects of angiotensin II while amlodipine works by decreasing calcium ion entry into smooth muscle and heart muscle.

The combination was approved for medical use in the United States in 2009. The combination is on the World Health Organization's List of Essential Medicines.{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }} It is available as a generic medication.{{cite web |title=Telmisartan and Amlodipine (Professional Patient Advice) |url=https://www.drugs.com/ppa/telmisartan-and-amlodipine.html |website=Drugs.com |accessdate=30 October 2019 }}